• 1

Limbal Stem Cell Deficiency – Allogeneic

We are recruiting patients with limbal stem cell deficiency (LSCD) for an international multicentric phase I/IIa clinical trial.

The aim of the trial is to assess the efficacy and safety of allogeneic ABCB5-positive limbal stem cells (ABCB5+ LSCs) in patients suffering from LSCD. It is examined whether application of ABCB5+ LSCs can result in regeneration of an intact cornea free from blood vessels. Primary safety endpoint is the occurrence of adverse events.

The trial has been approved by the German Paul Ehrlich Institute (PEI) and the U.S. Food and Drug Administration (FDA) as the competent national regulatory authorities. The European Medicines Agency (EMA) and the FDA has granted RHEACELL’s LSC product Orphan Drug Designation for the treatment of LSCD. The product has also received Fast-Track-Designation in the USA granted by the FDA.

For this trial 16 patients will be recruited in Germany and the USA.

For the manufacturing process of the allogeneic ABCB5+ LSCs we are using a patent hold by the Brigham and Women’s Hospital, Boston/USA, and the Children’s Hospital, Boston/USA, in cooperation with our scientific partner Prof. Dr. Markus Frank.

More information about the trial can be found HERE (ClinicalTrials.gov). You may also read a news release from Harvard Stem Cell Institute.

Background information about the use of ABCB5+ LSCs in LSCD can be found HERE.

<< back

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.